Paula Gould, PhD

VIENNA-Yes, size does matter, but it is certainly not the only way to monitor the effi cacy of cancer treatment. Th e way in which lesions are measured is extremely important as well, according to a special focus session on the assessment of tumor response at the 2009 European Congress of Radiology.

The likely consolidation of four international drug companies has raised concerns about the range of oncology agents that will remain in the R&D pipeline once the newly merged companies streamline their operations.